These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1. Ramirez-Montagut T; Andrews DM; Ihara A; Pervaiz S; Pandolfi F; Van Den Elsen PJ; Waitkus R; Boyle LA; Hishii M; Kurnick JT Clin Exp Immunol; 2000 Jan; 119(1):11-8. PubMed ID: 10606959 [TBL] [Abstract][Full Text] [Related]
24. Biological role of tyrosinase related protein and its biosynthesis and transport from TGN to stage I melanosome, late endosome, through gene transfection study. Jimbow K; Gomez PF; Toyofuku K; Chang D; Miura S; Tsujiya H; Park JS Pigment Cell Res; 1997 Aug; 10(4):206-13. PubMed ID: 9263327 [TBL] [Abstract][Full Text] [Related]
25. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590 [TBL] [Abstract][Full Text] [Related]
26. Expression of Melan-A in Spitz, pigmented spindle cell nevi, and congenital nevi: comparative immunohistochemical study. Evans MJ; Sanders DS; Grant JH; Blessing K Pediatr Dev Pathol; 2000; 3(1):36-9. PubMed ID: 10644168 [TBL] [Abstract][Full Text] [Related]
27. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones. Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640 [TBL] [Abstract][Full Text] [Related]
28. Intracellular vesicular trafficking of tyrosinase gene family protein in eu- and pheomelanosome biogenesis. Jimbow K; Hua C; Gomez PF; Hirosaki K; Shinoda K; Salopek TG; Matsusaka H; Jin HY; Yamashita T Pigment Cell Res; 2000; 13 Suppl 8():110-7. PubMed ID: 11041367 [TBL] [Abstract][Full Text] [Related]
29. A lumenal domain-dependent pathway for sorting to intralumenal vesicles of multivesicular endosomes involved in organelle morphogenesis. Theos AC; Truschel ST; Tenza D; Hurbain I; Harper DC; Berson JF; Thomas PC; Raposo G; Marks MS Dev Cell; 2006 Mar; 10(3):343-54. PubMed ID: 16516837 [TBL] [Abstract][Full Text] [Related]
30. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347 [TBL] [Abstract][Full Text] [Related]
31. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762 [TBL] [Abstract][Full Text] [Related]
32. Involvement of dynein and spectrin with early melanosome transport and melanosomal protein trafficking. Watabe H; Valencia JC; Le Pape E; Yamaguchi Y; Nakamura M; Rouzaud F; Hoashi T; Kawa Y; Mizoguchi M; Hearing VJ J Invest Dermatol; 2008 Jan; 128(1):162-74. PubMed ID: 17687388 [TBL] [Abstract][Full Text] [Related]
33. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550 [TBL] [Abstract][Full Text] [Related]
34. A model for melanosome biogenesis based on the purification and analysis of early melanosomes. Kushimoto T; Basrur V; Valencia J; Matsunaga J; Vieira WD; Ferrans VJ; Muller J; Appella E; Hearing VJ Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10698-703. PubMed ID: 11526213 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45. Shidham VB; Qi DY; Acker S; Kampalath B; Chang CC; George V; Komorowski R Am J Surg Pathol; 2001 Aug; 25(8):1039-46. PubMed ID: 11474288 [TBL] [Abstract][Full Text] [Related]
36. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours. Orosz Z Histopathology; 1999 Jun; 34(6):517-25. PubMed ID: 10383696 [TBL] [Abstract][Full Text] [Related]
37. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430 [TBL] [Abstract][Full Text] [Related]
38. Different approaches for assaying melanosome transfer. Berens W; Van Den Bossche K; Yoon TJ; Westbroek W; Valencia JC; Out CJ; Marie Naeyaert J; Hearing VJ; Lambert J Pigment Cell Res; 2005 Oct; 18(5):370-81. PubMed ID: 16162177 [TBL] [Abstract][Full Text] [Related]
40. The use of melanosomal proteins in the immunotherapy of melanoma. Kawakami Y; Robbins PF; Wang RF; Parkhurst M; Kang X; Rosenberg SA J Immunother; 1998 Jul; 21(4):237-46. PubMed ID: 9672845 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]